Small Dense Low-density Lipoprotein Cholesterol is a Useful Marker of Metabolic Syndrome in Patients with Coronary Artery Disease

Nozue, Tsuyoshi; Michishita, Ichiro; Ishibashi, Yutaka; Ito, Shin; Iwaki, Taku; Mizuguchi, Ichiro; Miura, Motohiro; Ito, Yasuki; Hirano, Tsutomu

doi:10.5551/jat.e507

Cited by 27 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The atherogenic dyslipidemia pattern, accepted to be due to insulin resistance in patients with MetS, is characterized by high triglyceride, low HDL-C, and increased sd-LDL particle levels 2) . Although LDL-C levels in patients with MetS were not found to be higher than in the general population, qualitative LDL-C abnormalities, such as sd-LDL, are commonly observed in these patient groups, with reports that LDL particle measurement may be a useful tool to identify candidates for intensive lipid-lowering treatment 17,18) . It has been stated that the therapeutic modulation of LDL size and subgroups would provide significant benefits in the risk reduction of cardiovascular events 13) .…”

Section: Discussionmentioning

confidence: 99%

Effects of Different Statin Treatments on Small Dense Low-Density Lipoprotein in Patients with Metabolic Syndrome

Bahadir¹,

Oğuz

Uzunlulu³

et al. 2009

JAT

View full text Add to dashboard Cite

Aim: To compare the effects of different low-density lipoprotein (LDL) cholesterol-lowering statin treatments on small dense LDL (sd-LDL) in hypercholesterolemic patients with metabolic syndrome (MetS). Methods: Forty hypercholesterolemic MetS patients ≥ 30 years of age were randomized to rosuvastatin (n 17) or other statins (n 23) groups. In the other statins group, those taking atorvastatin (n 12) were also evaluated separately. Statin doses were 10 mg/day rosuvastatin, 20 mg/day atorvastatin, 40 mg/day simvastatin, and 40 mg/day pravastatin. Treatment duration was planned to be 8 weeks. Sd-LDL levels were assessed at baseline and at the completion of treatment. Results: After treatment, sd-LDL levels were significantly reduced in all 3 groups (from 29.6 24.8 mg/dL to 8.9 8.5 mg/dL in the rosuvastatin group, p 0.001; from 26.2 15 mg/dL to 14.8 9.6 mg/dL in the atorvastatin group, p 0.02; and from 29.1 16.5 mg/dL to 14.7 11.2 mg/dL in the other statins group, p 0.0001). There was no significant difference in the mean percent changes among groups. Conclusion: Significant reduction in sd-LDL levels was observed after 8 weeks of statin treatment in hypercholesterolemic patients with MetS. This effect was similar for all statins and can be considered a class effect. J Atheroscler

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Different Statin Treatments on Small Dense Low-Density Lipoprotein in Patients with Metabolic Syndrome

Bahadir¹,

Oğuz

Uzunlulu³

et al. 2009

JAT

View full text Add to dashboard Cite

show abstract

“…A previous study based on gradient gel electrophoresis demonstrated subjects with metabolic syndrome to have small,dense LDL 22,25) . In a recent cross-sectional study, the number of small,dense LDL particles determined by nuclear magnetic resonance spectroscopy was found to be greater in patients with metabolic syndrome and to increase with the number of components of metabolic syndrome 26) .…”

Section: Discussionmentioning

confidence: 99%

Small,dense LDL and High-Sensitivity C-Reactive Protein (hs-CRP) in Metabolic Syndrome with Type 2 Diabetes Mellitus

Nakano

Kuboki

Matsumoto

et al. 2010

JAT

View full text Add to dashboard Cite

Aim:To clarify the clinical significance of small,dense LDL (sLDL) in the metabolic syndrome associated with type 2 diabetes. Methods: One hundred and ten healthy non-diabetic and non-metabolic syndrome subjects (58 male / 52 female), 77 non-metabolic diabetic subjects (62/15), 58 non-diabetic metabolic subjects (25/33), and 46 metabolic diabetic subjects (29/17) were enrolled in this study. Results:The subjects with metabolic syndrome (both with and without type 2 diabetes) had significantly higher fasting blood glucose, total-cholesterol (C), LDL-C, triglyceride, sLDL-C and hs-CRP levels than non-metabolic and non-diabetic subjects. HDL-C levels were significantly decreased in the former compared to the latter. Among the metabolic syndrome subjects, those with type 2 diabetes had significantly higher fasting blood glucose, systolic blood pressure and hs-CRP values than those without diabetes. sLDL-C, LDL-C and hs-CRP were the highest and HDL-C was lowest in the metabolic syndrome with diabetes group. A multiple regression analysis revealed the most significant determinant of sLDL-C to be LDL-C, followed by HDL-C, total-C, metabolic syndrome, type 2 diabetes mellitus, and triglyceride. Conclusion: Metabolic syndrome is a significant determinant of the plasma sLDL-C level. Hs-CRP was the highest in the metabolic syndrome patients with type 2 diabetes. Therefore, type 2 diabetes may further increase the risk of coronary artery disease in the metabolic syndrome subjects through cardiovascular inflammation. J Atheroscler Thromb, 2010; 17:410-415.

show abstract

“…In the present study, the highest and lowest levels of sd-LDL-C at baseline were 95 mg/dL and 24 mg/dL, revealing the variability of sd-LDL-C levels in FH. We previously reported that sd-LDL-C determined by this method was a useful marker of metabolic syndrome (MetS) in patients with CAD 30) . In this report, mean levels of sd-LDL-C with MetS were 26.4 2.6 mg/dL.…”

Section: Discussionmentioning

confidence: 99%

Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia

Nozue

Michishita

Ito

et al. 2008

JAT

Self Cite

View full text Add to dashboard Cite

Aim:The effects of statin on small dense low-density lipoprotein cholesterol (sd-LDL-C) and remnant-like particle cholesterol (RLP-C) levels in heterozygous familial hypercholesterolemia (FH) have not been examined. This study aimed to clarify the effects of statin on sd-LDL-C and RLP-C levels in heterozygous FH. Methods: Seventeen patients with heterozygous FH were randomly assigned to 2 mg/day pitavastatin or 10 mg/day atorvastatin. At baseline and 12 weeks after treatment with statin, we measured sd-LDL-C and RLP-C levels.

show abstract

Small Dense Low-density Lipoprotein Cholesterol is a Useful Marker of Metabolic Syndrome in Patients with Coronary Artery Disease

Abstract: Aim: An evaluation of the relation between small dense low-density lipoprotein cholesterol (sd-LDL-C) levels measured by the heparin-magnesium precipitation method and metabolic syndrome (MetS).

Cited by 27 publications

References 30 publications

Effects of Different Statin Treatments on Small Dense Low-Density Lipoprotein in Patients with Metabolic Syndrome

Effects of Different Statin Treatments on Small Dense Low-Density Lipoprotein in Patients with Metabolic Syndrome

Small,dense LDL and High-Sensitivity C-Reactive Protein (hs-CRP) in Metabolic Syndrome with Type 2 Diabetes Mellitus

Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia

Contact Info

Product

Resources

About